Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275664 · ClinicalTrials.gov registry record · NA
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
A NA study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT01275664: Clinical Trial NA study, sponsored by Gynecologic Oncology Group.
NCT01275664 is a NA study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01275664, a NA study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
Primary Outcome
Number of participants who had complete control defined by no vomiting
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Aprepitant
- PROCEDURE Adjuvant Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-06 |
| Phase | NA |
Why NCT01275664 stopped before completion
NCT01275664 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01275664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01275664 about?
NCT01275664 is a clinical study titled "Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer". This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vom...
What is the current status of trial NCT01275664?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2011-06.
What interventions are being tested in trial NCT01275664?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Aprepitant (DRUG), Adjuvant Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT01275664?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01275664's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia